The European Research Initiative on CLL (ERIC) 2020 Virtual Meeting, New Frontiers in CLL Research, was held on 1-3 October 2020. Leading experts in the field discussed the latest in CLL research, from basic to translational and clinical.

Highlights from this year’s ERIC International Meeting include gene and microenvironment cross-talk, rational use of biomarkers, patient stratification, novel therapeutic targets and appropriate patient management.

View all videos

ERIC 2020

European Research Initiative on CLL (ERIC) 2020 Virtual Meeting
01–03 October 2020 | Barcelona, Spain

This analysis was published recently in @BloodJournal

A BIG thank you for the worlwide collaboration that made possible one of the largest MRD studies in myeloma #mmsm

https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2022016782/486677/MRD-dynamics-during-maintenance-for-improved/ https://twitter.com/VJHemOnc/status/1575380146521083906

VJHemOnc@VJHemOnc

🎥 @BrunoPaiva_UNAV discusses the results of a pooled analysis of the TOURMALINE-MM3 and MM4 trials at #IMS2022:

👉http://ow.ly/iHYt50KVQEy👈

@Myeloma_Society #MMsm #HemOnc #mmMRD #BloodCancerAwarenessMonth

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

Load More...

ERIC 2020

European Research Initiative on CLL (ERIC) 2020 Virtual Meeting
01–03 October 2020 | Barcelona, Spain

The European Research Initiative on CLL (ERIC) 2020 Virtual Meeting, New Frontiers in CLL Research, was held on 1-3 October 2020. Leading experts in the field discussed the latest in CLL research, from basic to translational and clinical.

Highlights from this year’s ERIC International Meeting include gene and microenvironment cross-talk, rational use of biomarkers, patient stratification, novel therapeutic targets and appropriate patient management.

View all videos

This analysis was published recently in @BloodJournal

A BIG thank you for the worlwide collaboration that made possible one of the largest MRD studies in myeloma #mmsm

https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2022016782/486677/MRD-dynamics-during-maintenance-for-improved/ https://twitter.com/VJHemOnc/status/1575380146521083906

VJHemOnc@VJHemOnc

🎥 @BrunoPaiva_UNAV discusses the results of a pooled analysis of the TOURMALINE-MM3 and MM4 trials at #IMS2022:

👉http://ow.ly/iHYt50KVQEy👈

@Myeloma_Society #MMsm #HemOnc #mmMRD #BloodCancerAwarenessMonth

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter